Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

Hepatology

Volumn 54, Issue 2, 2011, Pages 443-451

  Zoutendijk, Roeland ^a   Reijnders, Jurriën G P ^a   Brown, Ashley ^b   Zoulim, Fabien ^c   Mutimer, David ^d   Deterding, Katja ^e   Petersen, Jörg ^f   Peter Hofmann, Wolf ^g   Buti, Maria ^h   Santantonio, Teresa ⁱ   van Bömmel, Florian ^j   Pradat, Pierre ^c   Oo, Ye ^d   Luetgehetmann, Marc ^k   Berg, Thomas ^j   Hansen, Bettina E ^a   Wedemeyer, Heiner ^e   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HÔTEL DIEU   (France)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ UNIVERSITY OF FOGGIA   (Italy)

^j Klinik und Poliklinik für Anästhesiologie und Intensivmedizin   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960727726     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24406     Document Type: Article

References (27)

1. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. HEPATOLOGY 2009; 49( 5 Suppl.): S112-S121.
2. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
3. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
4. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. HEPATOLOGY 2009; 49: 1503-1514.
5. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. HEPATOLOGY 2008; 48: 99-108.
6. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
7. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
8. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
9. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
11. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
12. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
13. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. HEPATOLOGY 2010; 51: 422-430.
14. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008; 13: 381-388.
15. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049.
16. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004; 40: 1421-1425.
17. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. HEPATOLOGY 2005; 41: 1391-1398.
18. Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362.
19. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089.
20. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-755.
21. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-1261.
22. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47: 366-372.
23. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290.
24. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-683.
25. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
26. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. HEPATOLOGY 2009; 50: 2001-2006.
27. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. HEPATOLOGY 2009; 49( 5 Suppl.): S185-S195.